Premium
Stem cells and diabetes treatment
Author(s) -
MADSEN OLE DRAGSBÆK
Publication year - 2005
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1600-0463.2005.apm_418.x
Subject(s) - neogenesis , induced pluripotent stem cell , stem cell , progenitor cell , embryonic stem cell , diabetes mellitus , insulin , biology , endogeny , cell , cellular differentiation , microbiology and biotechnology , endocrinology , immunology , islet , medicine , genetics , gene
Diabetes mellitus types 1 and 2 are characterized by absolute versus relative lack of insulin‐producing β cells, respectively. Reconstitution of a functional β‐cell mass by cell therapy – using organ donor islets of Langerhans – has been demonstrated to restore euglycaemia in the absence of insulin treatment. This remarkable achievement has stimulated the search for appropriate stem cell sources from which adequate expansion and maturation of therapeutic β cells can be achieved. This recent activity is reviewed and presented with particular focus on directed differentiation from pluripotent embryonic stem cells (versus other stem/progenitor cell sources) based on knowledge from pancreatic β‐cell development and the parallel approach to controlling endogenous β‐cell neogenesis.